荣昌生物
(688331)
| 流通市值：157.39亿 | | | 总市值：546.57亿 |
| 流通股本：1.62亿 | | | 总股本：5.64亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,719,833,029.78 | 1,097,953,438.31 | 525,968,624.06 | 1,716,861,688.03 |
| 营业收入 | 1,719,833,029.78 | 1,097,953,438.31 | 525,968,624.06 | 1,716,861,688.03 |
| 二、营业总成本 | 2,268,418,316.44 | 1,547,735,633.21 | 783,824,467.59 | 3,227,249,148.21 |
| 营业成本 | 270,593,449.58 | 175,019,080.53 | 88,030,755.91 | 337,163,495.25 |
| 税金及附加 | 12,367,642.39 | 7,942,580.41 | 3,664,250.31 | 15,367,036.06 |
| 销售费用 | 822,658,892.95 | 525,781,321.35 | 250,696,243.94 | 948,755,051.11 |
| 管理费用 | 215,621,316.7 | 146,312,149.24 | 90,180,354.01 | 316,705,122.82 |
| 研发费用 | 890,583,907.36 | 647,216,234.3 | 328,884,698.7 | 1,539,777,961.92 |
| 财务费用 | 56,593,107.46 | 45,464,267.38 | 22,368,164.72 | 69,480,481.05 |
| 其中:利息费用 | 57,040,326.33 | 41,811,862.2 | 21,288,381.85 | 72,378,603.57 |
| 其中:利息收入 | 3,570,684.25 | 2,439,986.87 | 1,480,937.23 | 10,239,381.13 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 293,722.97 | 52,149.71 | - | 1,537,475.88 |
| 加:投资收益 | -4,686,557.89 | -4,433,931.62 | -2,585,186.04 | -4,292,718.03 |
| 资产处置收益 | 205,690.01 | 178,554.91 | 61,138.48 | -704,096.08 |
| 资产减值损失(新) | -9,781.42 | - | - | -9,555,364.02 |
| 信用减值损失(新) | -3,632,557.18 | 2,058,764.7 | 4,455,456.92 | -11,088,107.95 |
| 其他收益 | 19,145,615.59 | 10,772,516.6 | 6,177,936.66 | 78,834,910.47 |
| 四、营业利润 | -537,269,154.58 | -441,154,140.6 | -249,746,497.51 | -1,455,655,359.91 |
| 加:营业外收入 | 797,697.78 | 178,676.42 | 170,293.76 | 398,734.03 |
| 减:营业外支出 | 14,229,118.58 | 8,593,198.89 | 4,568,266.31 | 13,104,176.67 |
| 五、利润总额 | -550,700,575.38 | -449,568,663.07 | -254,144,470.06 | -1,468,360,802.55 |
| 六、净利润 | -550,700,575.38 | -449,568,663.07 | -254,144,470.06 | -1,468,360,802.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -550,700,575.38 | -449,568,663.07 | -254,144,470.06 | -1,468,360,802.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -550,700,575.38 | -449,568,663.07 | -254,144,470.06 | -1,468,360,802.55 |
| 扣除非经常损益后的净利润 | -545,244,239.68 | -445,517,539.67 | -252,059,228.07 | -1,507,642,371.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.01 | -0.83 | -0.46 | -2.73 |
| (二)稀释每股收益 | -1.01 | -0.83 | -0.46 | -2.73 |
| 八、其他综合收益 | 49,592,840.32 | 30,010,415.8 | 11,992,969.57 | -30,878,101.93 |
| 归属于母公司股东的其他综合收益 | 49,592,840.32 | 30,010,415.8 | 11,992,969.57 | -30,878,101.93 |
| 九、综合收益总额 | -501,107,735.06 | -419,558,247.27 | -242,151,500.49 | -1,499,238,904.48 |
| 归属于母公司股东的综合收益总额 | -501,107,735.06 | -419,558,247.27 | -242,151,500.49 | -1,499,238,904.48 |
| 公告日期 | 2025-10-31 | 2025-08-23 | 2025-04-29 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |